Skip to main content
SpringerLink
Log in
Book cover

Gonadal Tissue Cryopreservation in Fertility Preservation pp 21–37Cite as

Controlled Ovarian Stimulation Protocols in Cancer Patients

  • Chapter
  • First Online:

  • 704 Accesses

Abstract

Embryo/oocyte cryopreservation is an effective method for fertility preservation in cancer patients. Determination of the controlled ovarian stimulation protocol and gonadotropin dose for oocyte/embryo cryopreservation requires an individualized assessment. Maximizing the number of embryos and oocytes cryopreserved during a fertility preservation cycle without causing ovarian hyperstimulation syndrome is extremely important, because the most of the patients have a single cycle opportunity due to time constraints before starting their oncologic treatment. In emergent settings, random-start ovarian stimulation is emerging as a new technique for the purpose of fertility preservation without compromising oocyte yield and maturity. Ovarian stimulation with tamoxifen or letrozole is highly recommended in patients with estrogen-sensitive cancers undergoing fertility preservation. While only a minority of the cancer patients has undergone thawing and embryo transfer, recent data of these modified protocols in egg donors and infertile patients have suggested that pregnancy outcomes are similar to those of conventional protocols.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER cancer statistics review, 1975–2009 (Vintage 2009 populations), National Cancer Institute. Bethesda. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed on 16 June 2015

  2. Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP (2012) Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 118(6):1710–1717

    Article  PubMed  Google Scholar 

  3. Letourneau JM, Melisko ME, Cedars MI, Rosen MP (2011) A changing perspective: improving access to fertility preservation. Nat Rev Clin Oncol 8(1):56–60

    Article  PubMed  Google Scholar 

  4. Rodriguez-Wallberg KA, Oktay K (2012) Options on fertility preservation in female cancer patients. Cancer Treat Rev 38(5):354–361

    Article  PubMed  Google Scholar 

  5. Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP (2012) Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer 118(7):1933–1939

    Article  PubMed  Google Scholar 

  6. Maltaris T, Seufert R, Fischl F, Schaffrath M, Pollow K, Koelbl H, Dittrich R (2007) The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol 130(2):148–155

    Article  PubMed  Google Scholar 

  7. Wallace WH, Thomson AB, Kelsey TW (2003) The radiosensitivity of the human oocyte. Hum Reprod 18(1):117–121

    Article  CAS  PubMed  Google Scholar 

  8. Meirow D, Nugent D (2001) The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 7(6):535–543

    Article  CAS  PubMed  Google Scholar 

  9. The Practice Committee of the American Society for Reproductive Medicine (2005) Fertility preservation and reproduction in cancer patients. Fertil Steril 83(6):1622–1628

    Article  Google Scholar 

  10. The Practice Committee of the American Society for Reproductive Medicine (2013) Mature oocyte cryopreservation: a guideline. Fertil Steril 99(1):37–43

    Article  Google Scholar 

  11. McLaren JF, Bates GW (2012) Fertility preservation in women of reproductive age with cancer. Am J Obstet Gynecol 207(6):455–462

    Article  PubMed  Google Scholar 

  12. Schachter M, Friedler S, Raziel A, Strassburger D, Bern O, Ron-el R (2001) Improvement of IVF outcome in poor responders by discontinuation of GnRH analogue during the gonadotropin stimulation phase – a function of improved embryo quality. J Assist Reprod Genet 18(4):197–204

    Article  CAS  PubMed  Google Scholar 

  13. Gougeon A (1986) Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod 1(2):81–87

    CAS  PubMed  Google Scholar 

  14. Pache TD, Wladimiroff JW, de Jong FH, Hop WC, Fauser BC (1990) Growth patterns of nondominant ovarian follicles during the normal menstrual cycle. Fertil Steril 54(4):638–642

    Article  CAS  PubMed  Google Scholar 

  15. McNatty KP, Hillier SG, van den Boogaard AM, Trimbos-Kemper TC, Reichert LE Jr, van Hall EV (1983) Follicular development during the luteal phase of the human menstrual cycle. J Clin Endocrinol Metab 56(5):1022–1031

    Article  CAS  PubMed  Google Scholar 

  16. Anderson RA, Kinniburgh D, Baird DT (1999) Preliminary experience of the use of a gonadotropin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment. Hum Reprod 14(10):2665–2668

    Article  CAS  PubMed  Google Scholar 

  17. Humaidan P, Bungum L, Bungum M, Hald F, Agerholm I, Blaabjerg J, Yding Andersen C, Lindenberg S (2005) Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. Reprod Biomed Online 11(6):679–684

    Article  CAS  PubMed  Google Scholar 

  18. von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, Strowitzki T (2009) Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 92(4):1360–1365

    Article  Google Scholar 

  19. Cakmak H, Katz A, Cedars MI, Rosen MP (2013) Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril 100(6):1673–1680. doi:10.1016/j.fertnstert.2013.07.1992

    Article  PubMed  Google Scholar 

  20. Sonmezer M, Turkcuoglu I, Coskun U, Oktay K (2011) Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril 95(6):2125, e2129–2111

    Article  PubMed  Google Scholar 

  21. Bedoschi GM, de Albuquerque FO, Ferriani RA, Navarro PA (2010) Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet 27(8):491–494

    Article  PubMed  PubMed Central  Google Scholar 

  22. Nayak SR, Wakim AN (2011) Random-start gonadotropin-releasing hormone (GnRH) antagonist-treated cycles with GnRH agonist trigger for fertility preservation. Fertil Steril 96(1):e51–e54. doi:10.1016/j.fertnstert.2011.04.079

    Article  PubMed  Google Scholar 

  23. Keskin U, Ercan CM, Yilmaz A, Babacan A, Korkmaz C, Duru NK, Ergun A (2014) Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature. J Pak Med Assoc 64(7):830–832

    PubMed  Google Scholar 

  24. Ozkaya E, San Roman G, Oktay K (2012) Luteal phase GnRHa trigger in random start fertility preservation cycles. J Assist Reprod Genet 29(6):503–505. doi:10.1007/s10815-012-9752-8

    Article  PubMed  PubMed Central  Google Scholar 

  25. Kim JH, Kim SK, Lee HJ, Lee JR, Jee BC, Suh CS, Kim SH (2015) Efficacy of random-start controlled ovarian stimulation in cancer patients. J Korean Med Sci 30(3):290–295. doi:10.3346/jkms.2015.30.3.290

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cakmak H, Mok-Lin E, Katz A, Harris E, Chin-Yu C, Cedars MI, Rosen MP (2014) Random start controlled ovarian stimulation results in high oocyte developmental competence and embryo quality. Fertil Steril 102(3):e164

    Article  Google Scholar 

  27. Checa MA, Brassesco M, Sastre M, Gomez M, Herrero J, Marque L, Brassesco A, Espinos JJ (2015) Random-start GnRH antagonist for emergency fertility preservation: a self-controlled trial. Int J Womens Health 7:219–225. doi:10.2147/IJWH.S66743

    Article  PubMed  PubMed Central  Google Scholar 

  28. Chen H, Wang Y, Lyu Q, Ai A, Fu Y, Tian H, Cai R, Hong Q, Chen Q, Shoham Z, Kuang Y (2015) Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles. Fertil Steril 103(5):1194–1201 e1192. doi:10.1016/j.fertnstert.2015.02.020

    Article  CAS  PubMed  Google Scholar 

  29. Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, Shoham Z (2014) Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril 101(1):105–111. doi:10.1016/j.fertnstert.2013.09.007

    Article  CAS  PubMed  Google Scholar 

  30. Martinez F, Clua E, Devesa M, Rodriguez I, Arroyo G, Gonzalez C, Sole M, Tur R, Coroleu B, Barri PN (2014) Comparison of starting ovarian stimulation on day 2 versus day 15 of the menstrual cycle in the same oocyte donor and pregnancy rates among the corresponding recipients of vitrified oocytes. Fertil Steril 102(5):1307–1311. doi:10.1016/j.fertnstert.2014.07.741

    Article  CAS  PubMed  Google Scholar 

  31. Reddy J, Oktay K (2012) Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril 98(6):1363–1369

    Article  CAS  PubMed  Google Scholar 

  32. Rodriguez-Wallberg KA, Oktay K (2010) Fertility preservation in women with breast cancer. Clin Obstet Gynecol 53(4):753–762

    Article  PubMed  PubMed Central  Google Scholar 

  33. (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists’ Collaborative Group. Lancet 339(8785):71–85

    Google Scholar 

  34. Fisk NM, Templeton AA, Papadopoulos GC, Matlin SA, Wu ZY (1989) Lack of effect of high-dose antioestrogen on the maturation and in-vitro fertilization of human oocytes. Hum Reprod 4(5):584–587

    CAS  PubMed  Google Scholar 

  35. Meirow D, Raanani H, Maman E, Paluch-Shimon S, Shapira M, Cohen Y, Kuchuk I, Hourvitz A, Levron J, Mozer-Mendel M, Brengauz M, Biderman H, Manela D, Catane R, Dor J, Orvieto R, Kaufman B (2014) Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil Steril 102(2):488–495 e483. doi:10.1016/j.fertnstert.2014.05.017

    Article  CAS  PubMed  Google Scholar 

  36. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z (2003) Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 18(1):90–95

    Article  CAS  PubMed  Google Scholar 

  37. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z (2005) Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23(19):4347–4353

    Article  CAS  PubMed  Google Scholar 

  38. Cole PA, Robinson CH (1990) Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 33(11):2933–2942

    Article  CAS  PubMed  Google Scholar 

  39. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348(24):2431–2442

    Article  CAS  PubMed  Google Scholar 

  40. Mitwally MF, Casper RF (2001) Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75(2):305–309

    Article  CAS  PubMed  Google Scholar 

  41. Testart J, Frydman R, Nahoul K, Grenier J, Feinstein MC, Roger M, Scholler R (1982) Steroids and gonadotropins during the last pre-ovulatory phase of the menstrual cycle. Time relationships between plasma hormones levels and luteinizing hormone surge onset. J Steroid Biochem 17(6):675–682

    Article  CAS  PubMed  Google Scholar 

  42. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, Bang H (2006) Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 91(10):3885–3890

    Article  CAS  PubMed  Google Scholar 

  43. Johnson LN, Dillon KE, Sammel MD, Efymow BL, Mainigi MA, Dokras A, Gracia CR (2013) Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod Biomed Online 26(4):337–344. doi:10.1016/j.rbmo.2013.01.003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Checa Vizcaino MA, Corchado AR, Cuadri ME, Comadran MG, Brassesco M, Carreras R (2012) The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. Reprod Biomed Online 24(6):606–610. doi:10.1016/j.rbmo.2012.02.020

    Article  CAS  PubMed  Google Scholar 

  45. Domingo J, Guillen V, Ayllon Y, Martinez M, Munoz E, Pellicer A, Garcia-Velasco JA (2012) Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril 97(4):930–934. doi:10.1016/j.fertnstert.2012.01.093

    Article  PubMed  Google Scholar 

  46. Revelli A, Porcu E, Levi Setti PE, Delle Piane L, Merlo DF, Anserini P (2013) Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol 29(11):993–996. doi:10.3109/09513590.2013.819083

    Article  CAS  PubMed  Google Scholar 

  47. Klein KO, Demers LM, Santner SJ, Baron J, Cutler GB Jr, Santen RJ (1995) Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J Clin Endocrinol Metab 80(9):2658–2660

    CAS  PubMed  Google Scholar 

  48. Azim AA, Costantini-Ferrando M, Lostritto K, Oktay K (2007) Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 92(6):2197–2200

    Article  CAS  PubMed  Google Scholar 

  49. Azim AA, Costantini-Ferrando M, Oktay K (2008) Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 26(16):2630–2635

    Article  CAS  PubMed  Google Scholar 

  50. Turan V, Bedoschi G, Moy F, Oktay K (2013) Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril 100(6):1681–1685 e1681. doi:10.1016/j.fertnstert.2013.08.030

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Azim A, Oktay K (2007) Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. Fertil Steril 88(3):657–664

    Article  CAS  PubMed  Google Scholar 

  52. Tiboni GM (2004) Aromatase inhibitors and teratogenesis. Fertil Steril 81(4):1158–1159; author reply 1159. doi:10.1016/j.fertnstert.2004.01.006

    Google Scholar 

  53. Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, Librach C, Greenblatt E, Casper RF (2006) Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 85(6):1761–1765. doi:10.1016/j.fertnstert.2006.03.014

    Article  CAS  PubMed  Google Scholar 

  54. Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H, Network NRM (2014) Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 371(2):119–129. doi:10.1056/NEJMoa1313517

    Article  PubMed  PubMed Central  Google Scholar 

  55. Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F (2015) Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. doi:10.1200/JCO.2014.59.3723

    PubMed  Google Scholar 

  56. Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R (2012) Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril 97(1):125–133

    Article  PubMed  Google Scholar 

  57. Agarwal A, Said TM (2004) Implications of systemic malignancies on human fertility. Reprod Biomed Online 9(6):673–679

    Article  PubMed  Google Scholar 

  58. Oktay K, Kim JY, Barad D, Babayev SN (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 28(2):240–244

    Article  CAS  PubMed  Google Scholar 

  59. Pal L, Leykin L, Schifren JL, Isaacson KB, Chang YC, Nikruil N, Chen Z, Toth TL (1998) Malignancy may adversely influence the quality and behaviour of oocytes. Hum Reprod 13(7):1837–1840

    Article  CAS  PubMed  Google Scholar 

  60. Das M, Shehata F, Moria A, Holzer H, Son WY, Tulandi T (2011) Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy. Fertil Steril 96(1):122–125

    Article  CAS  PubMed  Google Scholar 

  61. Knopman JM, Noyes N, Talebian S, Krey LC, Grifo JA, Licciardi F (2009) Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril 91(4 Suppl):1476–1478

    Article  PubMed  Google Scholar 

  62. Robertson AD, Missmer SA, Ginsburg ES (2011) Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. Fertil Steril 95(2):588–591

    Article  PubMed  Google Scholar 

  63. Klock SC, Zhang JX, Kazer RR (2010) Fertility preservation for female cancer patients: early clinical experience. Fertil Steril 94(1):149–155

    Article  PubMed  Google Scholar 

  64. Frattarelli JL, Levi AJ, Miller BT, Segars JH (2003) A prospective assessment of the predictive value of basal antral follicles in in vitro fertilization cycles. Fertil Steril 80(2):350–355

    Article  PubMed  Google Scholar 

  65. Delvigne A, Rozenberg S (2002) Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 8(6):559–577

    Article  CAS  PubMed  Google Scholar 

  66. Humaidan P, Kol S, Papanikolaou EG (2011) GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 17(4):510–524

    Article  CAS  PubMed  Google Scholar 

  67. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C (2008) The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 89(1):84–91

    Article  CAS  PubMed  Google Scholar 

  68. Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA (2010) GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 20(6):783–788

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Reddy J, Turan V, Bedoschi G, Moy F, Oktay K (2014) Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet 31(7):927–932. doi:10.1007/s10815-014-0248-6

    Article  PubMed  PubMed Central  Google Scholar 

  70. McArdle CA, Franklin J, Green L, Hislop JN (2002) Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. J Endocrinol 173(1):1–11

    Article  CAS  PubMed  Google Scholar 

  71. Blankstein J, Shalev J, Saadon T, Kukia EE, Rabinovici J, Pariente C, Lunenfeld B, Serr DM, Mashiach S (1987) Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil Steril 47(4):597–602

    Article  CAS  PubMed  Google Scholar 

  72. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P (2006) Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 85(1):112–120

    Article  CAS  PubMed  Google Scholar 

  73. Cakmak H, Fujimoto VY, Zamah AM, Rosen MP, Tran ND, Cedars MI, Rinaudo PF (2012) Metaphase II (MII) oocytes obtained at different time points in the same in vitro fertilization cycle. J Assist Reprod Genet 29(11):1203–1205

    Article  PubMed  PubMed Central  Google Scholar 

  74. Baerwald AR, Adams GP, Pierson RA (2012) Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update 18(1):73–91. doi:10.1093/humupd/dmr039

    Article  PubMed  Google Scholar 

  75. Xu B, Li Y (2013) Flexible ovarian stimulation in a poor responder: a case report and literature review. Reprod Biomed Online 26(4):378–383. doi:10.1016/j.rbmo.2012.11.020

    Article  CAS  PubMed  Google Scholar 

  76. Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, Shoham Z (2014) Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod Biomed Online 29(6):684–691. doi:10.1016/j.rbmo.2014.08.009

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, 6th Floor, 499 Illinois Street, San Francisco, CA, 94158, USA

    Hakan Cakmak & Mitchell P. Rosen

Authors
  1. Hakan Cakmak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitchell P. Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hakan Cakmak .

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, St. Marianna University School of Medici, Kawasaki, Kanagawa, Japan

    Nao Suzuki

  2. Societe de Recherche pour l'Inferti, Brussels, Belgium

    Jacques Donnez

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Japan

About this chapter

Cite this chapter

Cakmak, H., Rosen, M.P. (2016). Controlled Ovarian Stimulation Protocols in Cancer Patients. In: Suzuki, N., Donnez, J. (eds) Gonadal Tissue Cryopreservation in Fertility Preservation. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55963-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-55963-4_2

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-55961-0

  • Online ISBN: 978-4-431-55963-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation